La Jolla Pharmaceutical Overview
Latest P/E ratio for La Jolla Pharmaceutical: 10.67 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow10.67
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
La Jolla Pharmaceutical (LJPC) currently reports a P/E ratio of 10.67. That is below the Healthcare sector average of 27.42. Use the charts on this page to explore La Jolla Pharmaceutical's P/E ratio history and peer comparisons.
La Jolla Pharmaceutical's P/E ratio of 10.67 is lower than the Healthcare sector average of 27.42. That is roughly 61.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates La Jolla Pharmaceutical's market price to a fundamental measure such as earnings, sales, or book value. At 10.67, LJPC can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of 10.67, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 27.42. From there, open related valuation or income-statement pages for La Jolla Pharmaceutical, and consider following LJPC for alerts when major investors trade the stock.
La Jolla Pharmaceutical is classified in the Healthcare sector. On P/E ratio, it currently shows 10.67 versus a sector average near 27.42. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LJPC with unrelated industries.
